BioNTech Management Board Member Ryan Richardson to Step Down
BioNTech’s Chief Strategy Officer Ryan Richardson to Step Down After Pivotal Seven-Year Tenure BioNTech SE (Nasdaq: BNTX), the German-based global biotechnology company known for its groundbreaking work in mRNA technology…
EZMEKLY Receives Conditional Approval from European Commission
Merck and SpringWorks Secure Conditional EU Approval for EZMEKLY®, the First Therapy for NF1-Associated Plexiform Neurofibromas in Both Adults and Children Merck, a global leader in science and technology, announced…
Thermo Fisher and Sanofi Expand U.S. Drug Manufacturing Partnership
Thermo Fisher and Sanofi Expand Strategic Partnership with U.S. Sterile Manufacturing Deal Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in scientific services, has announced a significant expansion of…
PolyActiva Expands Leadership to Accelerate U.S. Growth and Clinical Progress
PolyActiva Strengthens Executive Team to Accelerate U.S. Expansion and Advance Late-Stage Clinical Development of Sustained-Release Ocular Therapies PolyActiva, a clinical-stage biopharmaceutical company at the forefront of innovation in ocular drug…
Tempus Secures FDA 510(k) Clearance for AI-Powered ECG-Low EF Diagnostic Software
Tempus Secures FDA 510(k) Clearance for AI-Driven ECG-Low EF Software, Expanding Capabilities in Cardiovascular Risk Detection Tempus AI, Inc. (NASDAQ: TEM), a trailblazer in applying artificial intelligence to drive precision…
FDA Grants RMAT Designation to Genascence’s GNSC-001 for Knee Osteoarthritis
Genascence Secures RMAT Designation for Groundbreaking Gene Therapy GNSC-001 in Knee Osteoarthritis, Signaling a Major Step Forward in Regenerative Medicine Genascence Corporation, a clinical-stage biotechnology company pioneering gene therapy solutions…
Satellos Names Dr. Wildon Farwell as Chief Medical Officer to Lead Clinical Strategy
Satellos Bioscience Names Renowned Neuromuscular Expert Dr. Wildon Farwell as Chief Medical Officer to Advance Duchenne Therapy Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a biotechnology company pioneering small molecule…
Veranex Launches MedTech’s First iCRO to Transform R&D Amid Tight Capital Climate
Veranex Launches Industry’s First Innovation CRO to Accelerate MedTech R&D in a Tight Capital Climate Veranex, a global leader in integrated product development and contract research services for medical technology,…
KalVista’s EKTERLY® (sebetralstat) Wins UK MHRA Nod as First Oral On-Demand HAE Treatment
KalVista Pharmaceuticals Secures UK MHRA Approval for EKTERLY® (sebetralstat), Paving the Way for First Oral On-Demand Treatment for Hereditary Angioedema in the Region KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage…
C2N Diagnostics Expands Alzheimer’s Blood Test Portfolio for Researchers
C2N Diagnostics Unveils Two Groundbreaking Blood Tests to Advance Alzheimer’s Research and Precision Diagnostics C2N Diagnostics, LLC, a trailblazer in brain health diagnostics, has announced the launch of two innovative…
Enveric’s EB-003 Shows Promise in Preclinical PTSD Model
Enveric Biosciences’ Lead Candidate EB-003 Shows Promising Preclinical Efficacy in PTSD Model, Signaling a Potential Breakthrough in Neuroplasticity-Based Psychiatric Treatment Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology company advancing a…
EyeDura’s Sustained-Release Eye Drop Technology Earns Dual Industry Accolades
EyeDura Therapeutics Wins Top Industry Honors as Its Sustained-Release Eye Drop Technology Gains Momentum in Ophthalmology Innovation EyeDura Therapeutics Inc., a trailblazing developer of preservative-free, sustained-release ophthalmic therapies, has garnered…